Menopause Treatment Through the Decades: A Complete History

Before Modern Medicine: How Menopause Was Understood for Centuries

For most of recorded history, the cessation of menstruation was interpreted through a moral and social lens rather than a physiological one. Menopause was thought to free the body from the "danger" of menstrual blood, and older women in many cultures were considered purified by the change. Medical interest was minimal because life expectancy rarely extended far beyond it.

By the 17th and 18th centuries, European physicians began cataloguing symptoms. The French physician Charles de Gardanne coined the term "ménopause" in 1821, giving the transition its first formal medical name. His framing, though, was still largely pathological: he described the climacteric as a crisis that required management through diet, bleeding, and rest.

Victorian Medicine: Rest, Hysteria, and Surgical Extremism

In the 19th century, menopause fell squarely within the broader Victorian obsession with "female nervous disorders." Hot flushes, mood changes, and insomnia were grouped under the umbrella of hysteria or neurasthenia. Standard advice included avoiding excitement, sexual abstinence, and prolonged bed rest, none of which addressed the underlying estrogen withdrawal.

The most dramatic intervention of this era was surgical oophorectomy, the removal of functioning ovaries, performed as a treatment for everything from pelvic pain to depression. Surgeon Robert Battey popularized the procedure in the 1870s; thousands of women underwent what his critics called "Battey's operation." Removing both ovaries in a premenopausal woman induces surgical menopause immediately, with vasomotor symptoms far more severe than natural menopause because the estrogen drop is abrupt rather than gradual. Women were made worse, not better, though the connection was not yet understood.

Early 20th Century: Recognizing the Ovarian Connection

By the 1890s, researchers had begun connecting ovarian function to systemic symptoms. In 1896, the first experiments with ovarian extracts suggested that something in the ovary could relieve menopausal complaints. By the 1920s, the hormone estrogen had been isolated and named. Scientists Edward Doisy and Edgar Allen identified estrone in 1923, and by the early 1930s synthetic and animal-derived estrogens were being tested in clinical settings.

The ovarian-deficiency model replaced the nervous-disorder model. Menopause was reframed as a hormonal deficiency state, a concept that would drive treatment for the rest of the 20th century, sometimes productively and sometimes recklessly.

The Estrogen Era: 1940s to 1970s

Premarin and the Promise of Perpetual Femininity

Conjugated equine estrogens (Premarin) received FDA approval in 1941, derived from the urine of pregnant mares. By the 1960s, it was one of the most prescribed drugs in the United States. Gynecologist Robert Wilson's 1966 bestseller "Feminine Forever" argued that menopause was a disease of estrogen deficiency and that women could and should remain "feminine" indefinitely through estrogen replacement. His framing was paternalistic and scientifically incomplete, but it drove prescriptions skyward.

Estrogen was prescribed not just for hot flushes but for aging skin, mood, memory, and cardiovascular protection. The evidence base for most of these uses was observational at best. What Wilson and his contemporaries missed was the role of the uterus: giving estrogen alone to women who still had a uterus dramatically increased the risk of endometrial hyperplasia and endometrial cancer.

The Endometrial Cancer Crisis of the 1970s

By the mid-1970s, multiple studies showed that women taking unopposed estrogen (estrogen without progestogen) had 5 to 10 times the risk of endometrial cancer compared with non-users. This finding, published in the New England Journal of Medicine in 1975 and confirmed in rapid succession by at least five additional case-control studies, sent prescriptions into a sharp decline.

The solution emerged within a few years: adding a progestogen to estrogen in women with a uterus. Combined estrogen-progestogen therapy protected the endometrium. By the early 1980s, combination hormone therapy had largely replaced unopposed estrogen in women who had not had a hysterectomy, and prescriptions recovered. The lesson, that the uterus changes the risk equation entirely, remains central to prescribing today.

The 1980s and 1990s: Observational Optimism and Growing Complexity

Cardiovascular Hope and the Nurses' Health Study

The Nurses' Health Study, a large prospective cohort that began enrolling women in 1976, produced a series of findings in the 1980s and 1990s suggesting that postmenopausal hormone therapy reduced coronary heart disease risk by as much as 35 to 50%. This observational data came from healthy women who chose to take hormones, a group that differed from non-users in ways that epidemiologists call the "healthy user bias," but the magnitude of apparent benefit generated enormous enthusiasm.

By the late 1990s, hormone therapy was being promoted as a long-term cardioprotective strategy. Primary care physicians prescribed it for women well into their 60s and 70s, sometimes regardless of symptom burden, based on the assumption that it would reduce heart attacks and strokes.

The PEPI Trial and Progestogen Debates

The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1995, was the first major randomized controlled trial to compare different hormone therapy formulations in 875 postmenopausal women. It confirmed that estrogen improved HDL cholesterol and that adding medroxyprogesterone acetate (MPA) partially blunted this benefit, while micronized progesterone preserved more of the HDL improvement. This finding planted the early seeds of the question that still matters today: not just whether to use hormones, but which formulation.

The PEPI trial also reinforced the endometrial safety message: women randomized to estrogen alone without a progestogen had significantly higher rates of endometrial hyperplasia.

2002: The WHI and the Great Reversal

What the Women's Health Initiative Actually Found

The Women's Health Initiative (WHI) was a landmark set of randomized controlled trials launched by the NIH in 1991, enrolling over 160,000 postmenopausal women. The estrogen-plus-progestogen arm, using conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily, was stopped early in July 2002 after a mean of 5.2 years.

The trial reported increased risks of breast cancer (hazard ratio 1.26), coronary heart disease (HR 1.29), stroke (HR 1.41), and pulmonary embolism (HR 2.13) in the treated group. The news was dramatic. Prescriptions for hormone therapy fell by more than 50% within two years. Many clinicians stopped prescribing it entirely, and women who had been using it for years stopped abruptly, often returning to debilitating vasomotor symptoms.

What Was Misunderstood About the WHI

The population enrolled in the WHI was not representative of women who typically seek hormone therapy for symptom relief. The average age at enrollment was 63 years, more than a decade past the average age of menopause. Over two-thirds of participants had never used hormone therapy before, meaning many entered the trial with pre-existing subclinical cardiovascular disease. The "timing hypothesis," now well-supported, holds that starting hormone therapy in older women with established atherosclerosis differs fundamentally from starting it in recently menopausal women with healthy vasculature.

The estrogen-alone arm of the WHI, which enrolled women who had previously had a hysterectomy, told a different story. Women aged 50 to 59 taking conjugated equine estrogen alone showed a 30% lower all-cause mortality and a non-significant trend toward fewer breast cancers compared with placebo. This arm was largely overshadowed by the combined-therapy findings in public coverage.

The aftermath of 2002 produced what menopause specialists now call the "WHI generation gap": a cohort of women in their late 40s and 50s during the 2000s and 2010s who were undertreated for significant vasomotor and genitourinary symptoms because both patients and clinicians had absorbed an oversimplified reading of the trial. Research published in Menopause in 2023 estimated that the sharp decline in hormone therapy use after 2002 may have been associated with tens of thousands of excess deaths among women aged 50 to 59, primarily from cardiovascular disease and osteoporosis-related fractures.

The 2010s: Rehabilitation, Nuance, and the Timing Hypothesis

KEEPS, DOPS, and Restoring Confidence

Two randomized trials published in the 2010s specifically addressed younger, recently menopausal women and helped rehabilitate the evidence base.

The Kronos Early Estrogen Prevention Study (KEEPS), published in 2014, enrolled 727 recently menopausal women aged 42 to 58 and randomized them to oral conjugated estrogen, transdermal estradiol, or placebo for four years. Neither active arm showed increased cardiovascular risk. Transdermal estradiol showed a favorable effect on mood symptoms.

The Danish Osteoporosis Prevention Study (DOPS), a 10-year randomized trial, found that women who began hormone therapy soon after menopause had significantly lower rates of heart failure, myocardial infarction, and osteoporotic fracture compared with controls, without a significant increase in cancer or stroke.

These trials were smaller than the WHI, but their populations matched the women most likely to benefit: recently menopausal, symptomatic, and cardiovascular-healthy.

Route of Administration Enters the Conversation

Observational data, particularly from French and British cohorts, began distinguishing between oral and transdermal estrogen. Oral estrogen undergoes first-pass hepatic metabolism, raising clotting factors and increasing venous thromboembolism (VTE) risk. Transdermal estradiol, which bypasses the liver, carries a substantially lower VTE risk, an important consideration for women with obesity, migraine with aura, or a personal history of clot. This distinction is now embedded in society guidelines.

Similarly, the type of progestogen began to matter more in clinical discussions. Micronized progesterone (Prometrium and generics) appears to carry a lower breast cancer risk signal than synthetic progestins like medroxyprogesterone acetate, based on the E3N French cohort and supported by biological plausibility, though head-to-head randomized data remain limited.

Life-Stage Specifics: How Treatment History Differs Across the Reproductive Spectrum

Perimenopause (Typically Ages 40 to 51)

Perimenopause is the transition phase characterized by erratic estrogen fluctuations, irregular cycles, and often the most new vasomotor symptoms. Historically, perimenopausal women were told to wait until menopause was confirmed before starting treatment. Current guidance from The Menopause Society recognizes that symptom burden during perimenopause can be severe and warrants treatment.

Low-dose hormonal contraceptives are often used in perimenopause because they suppress the erratic ovarian fluctuations, provide contraception (perimenopausal women remain fertile until proven otherwise), and manage vasomotor symptoms simultaneously. This is distinct from postmenopausal hormone therapy in dose and formulation.

Surgical and Medical Menopause (Any Age)

Women who undergo bilateral oophorectomy before natural menopause experience an abrupt estrogen withdrawal that produces more severe vasomotor symptoms than the gradual decline of natural menopause. Historically, surgical menopause was undertreated, particularly in women who had surgery for benign conditions. Current ACOG guidance supports hormone therapy in women with surgical menopause at least until the average age of natural menopause (51), given the added cardiovascular and bone risks of prolonged estrogen deprivation.

Premature Ovarian Insufficiency (Under Age 40)

Women with premature ovarian insufficiency (POI) face decades of estrogen deficiency before natural menopause would have occurred. The historical failure to treat POI adequately has left a legacy of excess cardiovascular events and osteoporosis in this population. ACOG recommends hormone therapy through at least age 51 for women with POI, independent of symptom burden, to reduce long-term morbidity.

PCOS and Menopause

Women with polycystic ovary syndrome (PCOS) often experience a different menopause transition: their cycles may become more regular in their late 40s as androgen levels decline, and the hyperandrogenic features of their reproductive years partially attenuate. However, the metabolic burden of PCOS, including insulin resistance and dyslipidemia, interacts with the postmenopausal metabolic shift and may modify hormone therapy risk-benefit calculations. Evidence in this specific group remains thin, and clinicians should individualize decisions carefully.

Today: The 2022 Menopause Society Position Statement and Where We Stand

The Menopause Society 2022 Hormone Therapy Position Statement represents the clearest synthesis of evidence to date. Its core conclusions:

• Hormone therapy is the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause (GSM).
• For healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks.
• The risk-benefit calculation shifts for women who are older, further from menopause, or who have cardiovascular risk factors or a personal history of breast cancer.
• Transdermal estradiol and micronized progesterone are preferred formulations when minimizing VTE and breast cancer risk is a priority.
• There is no mandatory duration limit for hormone therapy; duration should be individualized based on symptom burden and ongoing risk assessment.

ACOG Practice Bulletin 141 aligns closely with this framework. Both organizations explicitly state that the WHI findings should not be generalized to all women or all hormone preparations.

Non-hormonal options have also advanced substantially. The FDA approved fezolinetant (Veozah), a neurokinin 3 receptor antagonist, in May 2023, offering the first non-hormonal prescription mechanism specifically targeting the thermoregulatory pathway disrupted by estrogen loss. This matters for women who cannot or choose not to use hormone therapy, including those with estrogen-receptor-positive breast cancer.

Bone Health: An Underappreciated Thread Through the History

Estrogen's role in maintaining bone density has been understood since the 1940s, but systematic treatment of postmenopausal bone loss did not arrive until bisphosphonates entered clinical practice in the 1990s. Alendronate (Fosamax) received FDA approval for osteoporosis prevention and treatment in 1995 and 1997, giving clinicians a non-hormonal option for skeletal protection.

Today, bone health management in menopause is separated from vasomotor symptom management. Hormone therapy reduces fracture risk and is an appropriate choice when a woman also has vasomotor symptoms, but it is not primarily prescribed for bone protection alone. Women who have been on long-term hormone therapy and stop should discuss transitional bone density monitoring with their clinician.

What the Evidence Gap Means for You

Women have been under-represented in clinical trials across most of medical history. The WHI, despite its flaws, was in some ways a corrective: it enrolled only women. Still, it enrolled the wrong age group for the primary clinical question. The KEEPS and DOPS trials were more representative but far smaller.

What this means practically: extrapolations from WHI data to younger, recently menopausal women are not fully supported by that trial's own data. The evidence for transdermal over oral estrogen, and micronized progesterone over MPA, comes largely from observational data rather than head-to-head randomized trials. Your clinician is making recommendations in a space where the best available evidence is strong in some areas and genuinely limited in others, and intellectual honesty about that gap is part of good care.

Who This History Is Most Relevant For

Women Who Should Know This Context

• You are in perimenopause or early postmenopause and have been told "the hormones aren't safe" without further nuance. The blanket prohibition stems from an incomplete reading of 2002-era data.
• You had surgical menopause and were not offered hormone therapy. Historically, this was common and is now recognized as undertreating a preventable risk.
• You have POI and are under 40. The historic failure to treat POI is a documented harm.
• You are a breast cancer survivor asking about non-hormonal options. Fezolinetant and other non-hormonal agents now provide evidence-based alternatives.

Women for Whom Hormone Therapy Carries Meaningful Caution

• Active or recent estrogen-receptor-positive breast cancer (hormone therapy is generally contraindicated).
• Unexplained vaginal bleeding (requires evaluation before starting hormones).
• Active thromboembolic disease or a strong personal history of VTE (transdermal route substantially reduces but does not eliminate risk; discuss with your clinician).
• Uncontrolled cardiovascular disease.